KIORA PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KIORA PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $16.02M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 25, 2025 |
| FY2018 | Dec 31, 2018 | $1.65M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $407.5K | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Jul 7, 2022 |
| FY2021 | Dec 31, 2020 | $12.1K | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $2.69M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.65M | Mar 4, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $407.5K | Mar 2, 2018 |
| FY2017 | Dec 31, 2016 | $669.3K | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 23, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.84M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.59M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($12.51M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($13.58M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($13.77M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.86M) | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | ($7.10M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($10.81M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($13.22M) | Mar 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.83M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.51M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($12.59M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($12.31M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($14.24M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.87M) | Jul 7, 2022 |
| FY2018 | Dec 31, 2018 | ($10.84M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.78M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.84M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $4.03M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.45M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $5.35M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.57M | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $5.39M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $8.06M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $10.33M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.42M | Mar 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.96M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.56M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($9.56M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($10.43M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($10.68M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($7.32M) | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | ($8.15M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($10.84M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($6.47M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.41M) | Mar 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.8K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.3K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 25, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $63.9K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $20.1K | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $20.0K | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $37.0K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.25M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $36.48M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $13.71M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $18.68M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $20.13M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $15.30M | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $10.11M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $14.28M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $14.31M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.73M | Mar 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.13M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.72M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.60M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $7.27M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $5.55M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $5.57M | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.49M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.34M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $16.23M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $10.06M | Mar 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.13M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $25.76M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $6.11M | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $11.41M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $14.58M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $9.73M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $6.62M | Jul 7, 2022 |
| FY2020 | Dec 31, 2018 | $8.94M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($1.93M) | Mar 4, 2020 |
| FY2017 | Dec 31, 2016 | ($329.4K) | Mar 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.63M | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.53M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.53M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $1.53M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($154.22M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($143.38M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($146.98M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($134.46M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($120.88M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($107.11M) | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | ($100.25M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($93.15M) | Mar 4, 2020 |
| FY2018 | Jan 2, 2018 | ($82.34M) | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | ($91.82M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.70M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.79M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.45M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $5.96M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $7.85M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.19M | Jul 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.78M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $8.00M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $7.81M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.64M | Mar 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (24) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (18) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (57) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Jul 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (24) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (18) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (57) | Mar 23, 2023 |
| FY2021 | Sep 30, 2021 | 0 | Jul 7, 2022 |
| FY2021 | Dec 31, 2020 | (1) | Jul 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.76M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 3.00M | Mar 25, 2026 |
| FY2025 | Jun 11, 2024 | 2.97M | Mar 25, 2026 |
| FY2025 | Jun 10, 2024 | 26.74M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 856,182 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 1.80M | Mar 25, 2024 |
| FY2023 | Sep 27, 2022 | 1.08M | Mar 25, 2024 |
| FY2023 | Sep 26, 2022 | 43.16M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 316,599 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 5.56M | Jul 7, 2022 |